✦ LIBER ✦

TRV120027, a β-Arrestin Biased Ligand at the Angiotensin II Type 1 Receptor, Produces Unique Pharmacology and Is a Novel Potential Therapy for Heart Failure

✍ Scribed by Jonathan D. Violin; David G. Soergel; Scott M. DeWire; Dennis Yamashita; David Rominger; Erin J. Whalen; Maxine Gowen; Michael W. Lark

Book ID: 116340237
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 57 KB
Volume: 16
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2010.06.247

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiorenal Actions of TRV120027, a Nove

Cardiorenal Actions of TRV120027, a Novel, β-Arrestin-Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure

✍ Guido Boerrigter; Erin J. Whalen; Michael Lark; John C. Burnett 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 138 KB

TRV120027, a Novel -Arrestin Biased Liga

TRV120027, a Novel -Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure

✍ Boerrigter, G.; Soergel, D. G.; Violin, J. D.; Lark, M. W.; Burnett, J. C. 📂 Article 📅 2012 🏛 Ovid Technologies Wolters Kluwer -American Heart A 🌐 English ⚖ 827 KB

TRV120027, a Novel Beta-Arrestin Biased

TRV120027, a Novel Beta-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure

✍ Guido Boerrigter; David G. Soergel; Michael W. Lark; John C. Burnett Jr. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 319 KB